Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Barbara, Ink"'
Autor:
Philip J. Mease, Joseph F. Merola, Yoshiya Tanaka, Laure Gossec, Iain B. McInnes, Christopher T. Ritchlin, Robert B. M. Landewé, Akihiko Asahina, Barbara Ink, Andrea Heinrichs, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Laura C. Coates
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 5, Pp 1363-1382 (2024)
Abstract Introduction Psoriatic arthritis (PsA) is a chronic inflammatory disease requiring long-term treatment. Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated tolerabili
Externí odkaz:
https://doaj.org/article/4bbb5fc59b154e17b4cb6d05b6603d8e
Publikováno v:
Therapeutic Advances in Chronic Disease, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/15899ffc37384d03b24531cbac4e670c
Autor:
Joseph F Merola, Philip J Mease, Dafna D Gladman, M Elaine Husni, Nadine Goldammer, Jason Coarse, William Tillett, Vanessa Taieb, Jeremy Lambert, Barbara Ink
Publikováno v:
RMD Open, Vol 10, Iss 3 (2024)
Objectives To assess impact of bimekizumab treatment on patient-reported outcomes and health-related quality of life (HRQoL) in patients with active psoriatic arthritis (PsA), using 16-week data from two phase 3 studies.Methods BE OPTIMAL (NCT0389520
Externí odkaz:
https://doaj.org/article/6b47e439da8445b083e973aca1ddd188
Autor:
Robert Landewé, Joseph F Merola, Laure Gossec, Frank Behrens, Ana-Maria Orbai, Philip J Mease, Iain B McInnes, Dafna D Gladman, Laura C Coates, Alice B Gottlieb, Vishvesh Shende, Jason Coarse, Christopher T Ritchlin, Richard B Warren, Akihiko Asahina, Barbara Ink, Rajan Bajracharya
Publikováno v:
RMD Open, Vol 10, Iss 1 (2024)
Objectives To assess 52-week safety and efficacy of bimekizumab in patients with active psoriatic arthritis (PsA) and prior inadequate response/intolerance to tumour necrosis factor inhibitors.Methods Patients completing the 16-week phase III double-
Externí odkaz:
https://doaj.org/article/8c6f7873019c4474b1623173fd071db0
Autor:
Laure Gossec, Ana-Maria Orbai, Maarten de Wit, Dafna D Gladman, Laura C Coates, Alexis Ogdie, Vanessa Taieb, Jeremy Lambert, Barbara Ink, Christopher G Pelligra, Valérie Ciaravino
Publikováno v:
RMD Open, Vol 10, Iss 1 (2024)
Objectives To investigate psychometric performance of the 12-item Psoriatic Arthritis Impact of Disease (PsAID-12) total and individual item scores in patients with psoriatic arthritis (PsA) and to estimate score change thresholds and scores correspo
Externí odkaz:
https://doaj.org/article/aa2336a6b90d4afeb287bfb5c55eaac9
Autor:
Laura C. Coates, Iain B. McInnes, Joseph F. Merola, Richard B. Warren, Arthur Kavanaugh, Alice B. Gottlieb, Laure Gossec, Deepak Assudani, Rajan Bajracharya, Jason Coarse, Barbara Ink, Christopher T. Ritchlin
Publikováno v:
Arthritis & Rheumatology. 74:1959-1970
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98fa14569d76b9874f6c27123076d32a
https://doi.org/10.1002/art.42280
https://doi.org/10.1002/art.42280
Autor:
Philip J Mease, Akihiko Asahina, Dafna D Gladman, Yoshiya Tanaka, William Tillett, Barbara Ink, Deepak Assudani, Christine de la Loge, Jason Coarse, Jason Eells, Laure Gossec
Publikováno v:
Rheumatology
Rheumatology, 2022, pp.keac353. ⟨10.1093/rheumatology/keac353⟩
Rheumatology, 2022, pp.keac353. ⟨10.1093/rheumatology/keac353⟩
Objectives Evaluate effects of long-term bimekizumab treatment on patient-reported outcome (PRO) measures, symptoms and the impact of PsA on patients. Methods Patients with active PsA were enrolled into BE ACTIVE, a 48-week randomised controlled tria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7c8e89ef9a64ea25b3d7bd7dee60250
https://doi.org/10.1093/rheumatology/keac353
https://doi.org/10.1093/rheumatology/keac353
Autor:
Poonam Sharma, Deepak R Jadon, Dennis McGonagle, Barbara Ink, Deepak Assudani, Vanessa Taieb, Laura C Coates
Publikováno v:
Rheumatology. 62
Background/Aims Bimekizumab (BKZ) is a humanised monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A and has demonstrated clinical effectiveness in both joint and skin outcomes in patients with active psoriatic arthritis (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ee4e6678efae933e70849bc400cb07ab
https://doi.org/10.1093/rheumatology/kead104.230
https://doi.org/10.1093/rheumatology/kead104.230
Publikováno v:
Rheumatology. 62
Background/Aims Bimekizumab (BKZ) is a humanised monoclonal IgG1 antibody that acts by selectively inhibiting IL-17F in addition to IL-17A and has demonstrated clinical efficacy vs placebo (PBO) in both joint and skin outcomes in patients with active
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f9696ab5f84592449a6e292164f47e4
https://doi.org/10.1093/rheumatology/kead104.212
https://doi.org/10.1093/rheumatology/kead104.212
Autor:
Laura C, Coates, Iain B, McInnes, Joseph F, Merola, Richard B, Warren, Arthur, Kavanaugh, Alice B, Gottlieb, Laure, Gossec, Deepak, Assudani, Rajan, Bajracharya, Jason, Coarse, Barbara, Ink, Christopher T, Ritchlin
Publikováno v:
Arthritisrheumatology (Hoboken, N.J.)REFERENCES.
To assess the long-term safety, tolerability, and efficacy of bimekizumab in active psoriatic arthritis (PsA).Adult patients with active PsA who completed the double- and dose-blind periods of the BE ACTIVE randomized controlled trial were eligible t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::303fb0b41deb4f8b3d1ab70bfd483714
https://pubmed.ncbi.nlm.nih.gov/35922551
https://pubmed.ncbi.nlm.nih.gov/35922551